Thormohlensgt 51, 5006
75 articles with BerGenBio AS
Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and NSCLC confirmed as target indications for forward development towards registration, starting in 2019 Increasing confidence in bemcentinib safety profile with more than 250 patients dosed
BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio's second novel clinical candidate targeting AXL Phase I study will investigate safety and pharmacokinetics in healthy volunteers [09-January-2019] BERGEN, Norway, Jan. 9 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage bioph
BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS
Phase II monotherapy study of bemcentinib in high-risk MDS & AML
BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference
Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia
BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH
43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14)
BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.
Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients
BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial
Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective AXL inhibitor bemcentinib + KEYTRUDA in previously treated advanced NSCLC patients
BerGenBio ASA will announce its results for the third quarter 2018 on Tuesday, 13 November 2018.
BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC
Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC
BerGenBio Announces Interim Biomarker and Phase II Clinical Data with Selective AXL Inhibitor Bemcentinib Presented at ESMO
Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second line NSCLC
BerGenBio to Present Interim Phase II Clinical, Preclinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib at ESMO
BerGenBio ASA announces that the company and its collaborators will present interim clinical and biomarker data from its Phase II clinical programme with bemcentinib (BGB324)
BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in Combination With KEYTRUDA® in Patients With Advanced NSCLC
BerGenBio ASA announces that the first patient has been dosed in the second stage of the phase II trial (BGBC008) evaluating the Company's selective AXL inhibitor bemcentinib in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with previously treated advanced adenocarcinoma of the lung (non-small cell lung cancer, NSCLC) whose disease is progressing.
BerGenBio: Updated PhII Clinical Data With Selective AXL Inhibitor Bemcentinib Strengthens its Potential to Improve NSCLC Patient Outcomes
Overall response rate of 40% with the bemcentinib/KEYTRUDA combination observed in AXL-positive, previously treated NSCLC patients.
BerGenBio to Present Interim Phase 2 Clinical Data With Selective AXL Inhibitor Bemcentinib in Non-small Cell Lung Cancer at WCLC
BerGenBio ASA announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib at the 19th World Conference on Lung Cancer (WCLC) in Toronto (23 - 26 September 2018).
BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
BerGenBio ASA announces that Richard Godfrey, CEO of BerGenBio, is scheduled to present an overview of the Company's business and ongoing phase II clinical development programme with its first-in-class selective AXL inhibitor bemcentinib at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on September 5th 2018 at 9:35 AM (Eastern Time).
Encouraging clinical data emerging from several phase II trials with highly selective AXL inhibitor bemcentinib (BGB324)
Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA®
Clinical response merits initiation of stage 2 of the Phase II combination trial
BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib
BerGenBio ASA announces that interim data from its Phase II clinical development programme with bemcentinib, a selective AXL inhibitor, was presented at a reception hosted yesterday by the company in Chicago, IL, USA.
Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).